X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (497) 497
Book Review (144) 144
Publication (17) 17
Book Chapter (12) 12
Conference Proceeding (2) 2
Dissertation (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (281) 281
radiolabeled somatostatin analog (248) 248
humans (228) 228
radiology, nuclear medicine & medical imaging (220) 220
oncology (138) 138
neuroendocrine tumors (128) 128
receptor radionuclide therapy (115) 115
animals (103) 103
tumors (101) 101
peptides (91) 91
radionuclide therapy (86) 86
male (80) 80
survival (79) 79
radiopharmaceuticals - therapeutic use (75) 75
toxicity (75) 75
radiolabeled peptides (74) 74
female (72) 72
radiolabeled somatostatin analogs (71) 71
cancer (69) 69
peptide receptor radionuclide therapy (68) 68
octreotide - analogs & derivatives (65) 65
y-90-dotatoc (65) 65
nuclear medicine (61) 61
prrt (61) 61
neuroendocrine tumors - radiotherapy (60) 60
dosimetry (56) 56
medicine & public health (56) 56
octreotide - therapeutic use (56) 56
radiotherapy (56) 56
therapy (55) 55
lu-177-octreotate (49) 49
radionuclide imaging (47) 47
endocrinology & metabolism (46) 46
phase-ii (46) 46
imaging / radiology (45) 45
in-vivo (45) 45
radiopharmaceuticals (45) 45
lu-177-dotatate (44) 44
somatostatin - analogs & derivatives (44) 44
pharmacology & pharmacy (43) 43
middle aged (42) 42
octreotide (42) 42
somatostatin (41) 41
renal uptake (40) 40
mice (39) 39
adult (38) 38
tissue distribution (38) 38
phase-i (37) 37
positron-emission-tomography (37) 37
scintigraphy (37) 37
chemotherapy (36) 36
receptors, somatostatin - metabolism (36) 36
enets consensus guidelines (35) 35
octreotate (35) 35
cardiology (34) 34
liver metastases (33) 33
orthopedics (33) 33
prognostic-factors (33) 33
treatment outcome (33) 33
aged (32) 32
tyr octreotate (32) 32
medicine, research & experimental (31) 31
biochemistry & molecular biology (30) 30
biodistribution (30) 30
care and treatment (30) 30
diagnosis (30) 30
neuroendocrine tumors - therapy (30) 30
peptide (30) 30
receptors, peptide - metabolism (30) 30
lu-177-dota,tyr octreotate (29) 29
metastasis (29) 29
radioisotopes - therapeutic use (29) 29
rats (29) 29
carcinoid-tumors (28) 28
gastroenteropancreatic tumors (28) 28
radiopharmaceuticals - pharmacokinetics (28) 28
gastroenteropancreatic neuroendocrine tumors (27) 27
cell line, tumor (26) 26
neuroendocrine tumors - pathology (26) 26
neuroendocrine tumours (26) 26
radioisotopes (26) 26
analogs (25) 25
neoplasms - radiotherapy (25) 25
organometallic compounds - therapeutic use (25) 25
lu-177 (24) 24
management (24) 24
mice, nude (24) 24
somatostatin receptor (24) 24
expression (23) 23
endocrine tumors (22) 22
neuroendocrine tumors - metabolism (22) 22
radioimmunotherapy (22) 22
review (22) 22
somatostatin - therapeutic use (22) 22
somatostatin analogs (22) 22
biochemical research methods (21) 21
efficacy (21) 21
in-vitro (21) 21
localization (21) 21
neuroendocrine tumor (21) 21
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Bioconjugate Chemistry, ISSN 1043-1802, 2002, Volume 13, Issue 3, pp. 530 - 541
Journal Article
Journal Article
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, ISSN 0889-8529, 03/2011, Volume 40, Issue 1, pp. 187 - 187
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 01/2005, Volume 46, pp. 92S - 98S
The challenge for internal therapy is to deliver the highest possible dose to the tumor while sparing normal organs from damage. Currently, the potential risk... 
Y-90-DOTATOC | MARROW | dosimetry | TUMOR RESPONSE | MYELOTOXICITY | BIODISTRIBUTION | oncology | Y-90-DOTA-Tyr-octreotide | radionuclide therapy | MODELS | INTERNAL RADIOTHERAPY | RADIOLABELED ANTIBODIES | Y-90 SMT487 OCTREOTHER(TM) | PHASE-I | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
ANTICANCER RESEARCH, ISSN 0250-7005, 03/2012, Volume 32, Issue 3, pp. 815 - 822
Somatostatin receptor targeting is a valuable method to treat somatostatin receptor-positive tumours. In peptide receptor radionuclide therapy, it is essential... 
LOCALIZATION | OCTREOTIDE | LIMITATIONS | kidney uptake | RADIOLABELED PEPTIDES | Y-90/88 | BIODISTRIBUTION | MECHANISMS | Somatostatin analogue | RADIOPEPTIDES | ANTIBODY FRAGMENTS | ONCOLOGY | RECEPTOR RADIONUCLIDE THERAPY | RENAL UPTAKE | In-111
Journal Article
EUROPEAN JOURNAL OF ENDOCRINOLOGY, ISSN 0804-4643, 01/2015, Volume 172, Issue 1, pp. R1 - R8
Peptide receptor radionuclide therapy (PRRT) is a promising new treatment modality for inoperable or metastasized gastroenteropancreatic neuroendocrine tumors... 
RADIOLABELED SOMATOSTATIN ANALOG | SURVIVAL | Y-90-DOTATOC | Y-90 | LU-177-OCTREOTATE | ENDOCRINOLOGY & METABOLISM | PHASE-II | SALVAGE THERAPY | LU-177-DOTATATE | TOXICITY | CONVENTIONAL THERAPY
Journal Article
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, ISSN 1619-7070, 10/2011, Volume 38, Issue 10, pp. 1788 - 1797
Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine... 
RADIOLABELED SOMATOSTATIN ANALOG | Neuroendocrine tumours | Y-90 | Somatostatin receptor | radionuclide therapy | CARCINOID-SYNDROME | Y-90-DOTATATE | RENAL UPTAKE | Peptide receptor | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Lu-177-DOTATATE
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 16, pp. 4617 - 4624
Purpose: Bronchial and gastroenteropancreatic neuroendocrine tumors (NET) are slow-growing tumors, which frequently express somatostatin receptors on their... 
RADIOLABELED SOMATOSTATIN ANALOG | Y-90-DOTATOC | GRADING SYSTEM | PRRT | LU-177-OCTREOTATE | PROGNOSTIC-FACTORS | ONCOLOGY | GUIDELINES | RECEPTOR RADIONUCLIDE THERAPY | CHEMOTHERAPY | LANREOTIDE | Outcome Assessment (Health Care) - methods | Humans | Middle Aged | Male | Intestinal Neoplasms - radiotherapy | Leukemia - etiology | Time Factors | Aged, 80 and over | Organometallic Compounds - therapeutic use | Adult | Female | Stomach Neoplasms - radiotherapy | Acute Disease | Octreotide - analogs & derivatives | Organometallic Compounds - adverse effects | Kaplan-Meier Estimate | Octreotide - adverse effects | Pancreatic Neoplasms - radiotherapy | Treatment Outcome | Octreotide - therapeutic use | Myelodysplastic Syndromes - etiology | Neuroendocrine Tumors - radiotherapy | Bronchial Neoplasms - radiotherapy | Outcome Assessment (Health Care) - statistics & numerical data | Aged | Radiopharmaceuticals - adverse effects | Radiopharmaceuticals - therapeutic use | Therapy | Membranes | Toxicity | Leukemia | Liver | Radioisotopes | Myelodysplastic syndrome | Metastases | Confidence intervals | Receptors | Safety engineering | Somatostatin | Safety | Effectiveness | Kidneys | Cell membranes | Cell membranes (biology) | Survival | Patients | Lutetium | Experimental design | Renal failure | Somatostatin receptors | Tumors | Cancer | Neuroendocrine tumors | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
THERANOSTICS, ISSN 1838-7640, 2016, Volume 6, Issue 4, pp. 501 - 510
Purpose: To characterise efficacy and safety of Lu-177-DOTATOC as agent for peptide receptor radiotherapy (PRRT) of advanced neuroendocrine tumours (NET).... 
SURVIVAL | Y-90-DOTATOC | MEDICINE, RESEARCH & EXPERIMENTAL | somatostatin receptor | Neuroendocrine tumour | EFFICACY | TYR OCTREOTATE | somatostatin analogue | TOXICITY | RADIOLABELED SOMATOSTATIN ANALOG | radionuclide therapy | radiotherapy | peptide receptor | GRADE
Journal Article